Compare REXR & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REXR | SNN |
|---|---|---|
| Founded | 2013 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 13.9B |
| IPO Year | 2013 | 1999 |
| Metric | REXR | SNN |
|---|---|---|
| Price | $39.70 | $33.11 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $43.00 | $32.83 |
| AVG Volume (30 Days) | ★ 2.3M | 523.0K |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.41% | 2.21% |
| EPS Growth | 15.85 | ★ 59.91 |
| EPS | ★ 1.43 | 0.56 |
| Revenue | $997,931,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $9.35 | $7.71 |
| Revenue Next Year | $3.81 | $5.23 |
| P/E Ratio | ★ $27.35 | $59.38 |
| Revenue Growth | ★ 10.40 | 5.35 |
| 52 Week Low | $29.68 | $23.69 |
| 52 Week High | $44.38 | $38.79 |
| Indicator | REXR | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 49.90 |
| Support Level | $38.56 | $32.66 |
| Resistance Level | $41.44 | $33.25 |
| Average True Range (ATR) | 0.79 | 0.37 |
| MACD | -0.14 | 0.12 |
| Stochastic Oscillator | 35.88 | 68.18 |
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.